National Bank of Canada’s Travere Therapeutics TVTX Stock Holding History

National Bank of Canada’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$284	Buy	+5	New	+$222	﹤0.01%	2928
2024 Q3	–	Sell	-400	Closed	-$3.29K	–	3046
2024 Q2	$3.29K	Hold	400	–	–	﹤0.01%	2353
2024 Q1	$2.52K	Hold	400	–	–	﹤0.01%	2419
2023 Q4	$3.81K	Hold	400	–	–	﹤0.01%	2359
2023 Q3	$3.34K	Buy	+400	New	+$5.64K	﹤0.01%	2434
2023 Q2	–	Sell	-116,000	Closed	-$2.61M	–	2828
2023 Q1	$2.61M	Hold	116,000	–	–	0.01%	778
2022 Q4	$2.44M	Buy	116,000 +67,000	+137%	+$1.42M	0.01%	824
2022 Q3	$1.21M	Buy	+49,000	New	+$1.27M	0.01%	925

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

National Bank of Canada's TVTX Position: Q2 2026 in Review

National Bank of Canada opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 5 shares worth $284. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in TVTX as recently as Q2 2024.

National Bank of Canada first reported a position in TVTX in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.61M in Q1 2023. 121 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

National Bank of Canada held 5 shares of Travere Therapeutics worth $284 as of Q2 2026.
Travere Therapeutics was a new National Bank of Canada position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2928 holding.
National Bank of Canada first reported a position in Travere Therapeutics in Q3 2022 and has held it in 8 quarters since.
National Bank of Canada's Travere Therapeutics position peaked at $2.61M in Q1 2023.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.